Publications by authors named "N Pennell"
Unresectable stage III NSCLC is now treated with chemoradiation (CRT) followed by immune checkpoint inhibitors (ICI). Pneumonitis, a common CRT complication, has heightened risk with ICI, potentially causing severe outcomes. Currently, there are no biomarkers to predict pneumonitis risk or differentiate between radiation-induced pneumonitis (RTP) and ICI-induced pneumonitis (IIP).
View Article and Find Full Text PDFArticle Synopsis
- Selpercatinib is a RET inhibitor used to treat specific types of cancers, and a long-term safety analysis showed that most side effects can be managed with dose changes.
- The study included 837 patients with RET fusion-positive tumors, who were followed for an average of 45.4 months, revealing high rates of grade ≥3 adverse effects, primarily hypertension and elevated liver enzymes.
- Despite significant side effects, most patients were able to continue treatment, indicating that long-term use of selpercatinib is possible with appropriate management of adverse events.
Article Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC). Electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis. Of 3121 (21.
View Article and Find Full Text PDFWe assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review.
View Article and Find Full Text PDF